|
|
|
|
|
|
Beyond_borders
(pdf, 5.28 MB)
|
22 Apr, 2013
|
Global
|
We saw a strong performance by major biotech players, but a challenging environment for the rest of the industry. Read more ..
|
|
The Ernst and Young Deal Sentiment Scorecard
(pdf, 262.75 KB)
|
08 Apr, 2013
|
Global
|
What lies ahead in the deal space? Our scorecard is based on investor presentations, meetings and conversations around the 2013 J.P. Morgan Healthcare Conference.
|
|
SEC Comments and Trends
(pdf, 707.85 KB)
|
18 Feb, 2013
|
Global
|
As you head into the year-end reporting season, read our insights based on review of SEC staff comments on recent public life sciences company filings.
|
|
The shifting pharmaceutical industry landscape
(pdf, 7.41 MB)
|
07 Feb, 2013
|
Global
|
Accounting and regulatorytrends affecting reporting for2012 and planning for 2013
|
|
German Biotechnology Report 2012
(pdf, 4.21 MB)
|
17 Jan, 2013
|
Global
|
Presented in both German and English — EY's 13th German Biotech Report offers a thorough analysis of the biotech sector in Germany.
|
|
|
Prescriptions
(pdf, 248.51 KB)
|
04 Jan, 2013
|
Global
|
Big pharma’s growth challenge andimplications for deals
|
|
Closing_The_Gap_010213
(pdf, 346.16 KB)
|
04 Jan, 2013
|
Global
|
As big pharma faces a widening growth gap, our Firepower Index highlights industry's capacity for deals in 2013 and beyond.
|
|
|
Technical Line Implementing the medical device excise tax
(pdf, 99.49 KB)
|
06 Dec, 2012
|
Global
|
An excise tax1 of 2.3% on the sale, lease, rental or use of certain medical devices was mandated by the 2010 health care reform legislation
|
|
|
Pulse medical technology report 2012
(pdf, 3.58 MB)
|
25 Sep, 2012
|
Global
|
How do your financing and M&A plans compare to our annual findings? Know more.
|
|
Cash on the prescription 2012
(pdf, 756.46 KB)
|
12 Sep, 2012
|
Global
|
Cash on prescription 2012 is the latest in a series of working capital management reports published by Ernst & Young.
|
